Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naive patients with a baseline viral load of more than 100 000 copies/ml

被引：6
|
作者：
Nishijima, Takeshi [1 ,2 ]
Komatsu, Hirokazu [3 ]
Teruya, Katsuji [1 ]
Tanuma, Junko [1 ]
Tsukada, Kunihisa [1 ]
Gatanaga, Hiroyuki [1 ,2 ]
Kikuchi, Yoshimi [1 ]
Oka, Shinichi [1 ,2 ]
机构：
[1] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo 1620052, Japan
[2] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan
[3] Saku Cent Hosp, Dept Community Care, Nagano, Japan
来源：
AIDS | 2013年 / 27卷 / 05期
关键词：
TENOFOVIR DISOPROXIL FUMARATE; HIV-INFECTED PATIENTS; DARUNAVIR-RITONAVIR; ABACAVIR-LAMIVUDINE; RENAL SAFETY; EFFICACY; EMTRICITABINE; THERAPY; TRIALS;
D O I：
10.1097/QAD.0b013e32835cadb7
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The efficacy and safety of fixed-dose abacavir/lamivudine against tenofovir/emtricitabine, both with once-daily darunavir/ritonavir, was examined in 80 treatment-naive patients with a baseline HIV-1 viral load of more than 100 000 copies/ml. The time to virologic failure by 48 weeks was not different between the two groups. The percentage of patients with viral suppression was not significantly different with per protocol population. Tenofovir/emtricitabine showed better tolerability; more patients on abacavir/lamivudine changed regimen than those on tenofovir/emtricitabine. A randomized trial to elucidate the efficacy and safety of these two regimens is warranted.
引用
收藏
页码：839 / 842
页数：4
相关论文
共 28 条
  • [1] Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naive patients: a pilot study
    Nishijima, Takeshi
    Tsukada, Kunihisa
    Teruya, Katsuji
    Gatanaga, Hiroyuki
    Kikuchi, Yoshimi
    Oka, Shinichi
    AIDS, 2012, 26 (05) : 649 - 651
  • [2] Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naive and -Experienced Patients
    Boffito, Marta
    Miralles, Diego
    Hill, Andrew
    HIV CLINICAL TRIALS, 2008, 9 (06): : 418 - 427
  • [3] Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
    Stellbrink, Hans-Juergen
    Le Fevre, Eric
    Carr, Andrew
    Saag, Michael S.
    Mukwaya, Geoffrey
    Nozza, Silvia
    Valluri, Srinivas Rao
    Vourvahis, Manoli
    Rinehart, Alex R.
    McFadyen, Lynn
    Fichtenbaum, Carl
    Clark, Andrew
    Craig, Charles
    Fang, Annie F.
    Heera, Jayvant
    AIDS, 2016, 30 (08) : 1229 - 1238
  • [4] Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial
    Nishijima, Takeshi
    Takano, Misao
    Ishisaka, Michiyo
    Komatsu, Hirokazu
    Gatanaga, Hiroyuki
    Kikuchi, Yoshimi
    Endo, Tomoyuki
    Horiba, Masahide
    Kaneda, Satoru
    Uchiumi, Hideki
    Koibuchi, Tomohiko
    Naito, Toshio
    Yoshida, Masaki
    Tachikawa, Natsuo
    Ueda, Mikio
    Yokomaku, Yoshiyuki
    Fujii, Teruhisa
    Higasa, Satoshi
    Takada, Kiyonori
    Yamamoto, Masahiro
    Matsushita, Shuzo
    Tateyama, Masao
    Tanabe, Yoshinari
    Mitsuya, Hiroaki
    Oka, Shinichi
    INTERNAL MEDICINE, 2013, 52 (07) : 735 - 744
  • [5] Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Ortiz, Roberto
    DeJesus, Edwin
    Khanlou, Homayoon
    Voronin, Evgeniy
    van Lunzen, Jan
    Andrade-Villanueva, Jaime
    Fourie, Jan
    De Meyer, Sandra
    De Pauw, Martine
    Lefebvre, Eric
    Vangeneugden, Tony
    Spinosa-Guzman, Sabrina
    AIDS, 2008, 22 (12) : 1389 - 1397
  • [6] Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS
    Arathoon, E.
    Schneider, S.
    Baraldi, E.
    Lim, P. L.
    Opravil, M.
    Van De Casteele, T.
    Lavreys, L.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (01) : 12 - 17
  • [7] Viral Load Decay in Antiretroviral-Naive Patients Receiving Once-Daily Tenofovir and Emtricitabine plus Twice-Daily Nevirapine
    Amoroso, Anthony
    Gilliam, Bruce L.
    Talwani, Rohit
    Boyce, Colleen
    Redfield, Robert R.
    Davis, Charles E.
    HIV CLINICAL TRIALS, 2009, 10 (05): : 320 - 323
  • [8] Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/Ritonavir in HIV-1-Infected, Treatment-Naive ARTEMIS Patients at Week 96
    Fourie, Jan
    Flamm, Jason
    Rodriguez-French, Amalia
    Kilby, Don
    Domingo, Pere
    Lazzarin, Adriano
    Ballesteros, Juan
    Sosa, Nestor
    Van De Casteele, Tom
    DeMasi, Ralph
    Spinosa-Guzman, Sabrina
    Layreys, Ludo
    HIV CLINICAL TRIALS, 2011, 12 (06): : 313 - 322
  • [9] Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive HIV-1-infected ARTEMIS patients at week 96
    Baraldi, E.
    Morales-Ramirez, J.
    Schneider, S.
    Stoehr, A.
    Orani, A.
    Van De Casteele, T.
    Lavreys, L.
    Hill, A.
    ANTIVIRAL THERAPY, 2009, 14 (07) : A55 - A56
  • [10] Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients
    Khanlou, H
    Yeh, V
    Guyer, B
    Farthing, C
    AIDS PATIENT CARE AND STDS, 2005, 19 (03) : 135 - 140
123